SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: M.LUTH who wrote (817)1/8/1998 11:05:00 AM
From: MCorbley  Read Replies (1) of 1115
 
To: chirodoc (433 )
From: Michael Corbley
Monday, Aug 18 1997 2:31PM EST
Reply # of 817

Lidakol vs. Zovirax: In 1995, Lidak reported the results of a study comparing Lidakol to Zovirax (aciclovir)
5% cream in 326 patients. Lidakol demonstrated "statistically comparable therapeutic efficacy to Zovirax 5%
cream." (quote from annual report). Zovirax 5% cream is the standard approved treatment for cold sores in
Europe, but is not available in the U.S. This study was used to show that Lidakol was as effective as the best
treatment available, and by inference that Lidakol is effective--period. Lidak also pointed out that Zovirax 5%
cream is not the same as, and not as effective as, Zovirax 5% ointment, which is available in the U.S. for
limited use in other herpes infections but not for recurrent oral infections. That was in 1995.

European sales of Zovirax were $125 million US dollars in 1994.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News